rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Robert W. Ross

Director

Company insider

Files Form 4 as: Director, Obsidian Therapeutics; Director, Xilio Therapeutics; Chief Executive Officer, Surface Oncology.

Every Form 4 they filed

In numbers

Trades disclosed
30
Buys
0
Sells
10
Bought
$0
Sold
$429K
Companies
3
Companies where not an officer
2
First trade
4 Jan 2019
Last trade
3 Aug 2026
Last filed
5 Aug 2026

Companies traded

Where they are an officer
Surface OncologyDirector, Officer · last 8 Sep 20230 buys · 10 sells
Everywhere else they filed: board seats, 10% stakes, other companies
OBX Obsidian TherapeuticsDirector · Biotechnology · last 3 Aug 20260 buys · 0 sells
XLO Xilio TherapeuticsDirector · Biotechnology · last 11 Jun 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
3 Aug 2026filed 5 Aug 2026OBX Obsidian Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—37,653 at $0.00filing
3 Aug 2026filed 5 Aug 2026OBX Obsidian Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—37,653 at $0.00filing
11 Jun 2026filed 12 Jun 2026XLO Xilio Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—5,000 at $0.00filing
11 Jun 2026filed 12 Jun 2026XLO Xilio Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—5,000 at $0.00filing
11 Jun 2025filed 12 Jun 2025XLO Xilio Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—31,000 at $0.00filing
14 Jun 2024filed 17 Jun 2024XLO Xilio Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—25,000 at $0.00filing
8 Sep 2023filed 8 Sep 2023Surface Oncologyoption or derivativeSEC FORM 4 Code D—400,000 at $0.00filing
8 Sep 2023filed 8 Sep 2023Surface OncologySEC FORM 4 Code D—83,193filing
1 Aug 2023filed 11 Aug 2023Surface OncologySEC FORM 4 Sold$16K16,713 at $0.94filing
12 Jun 2023filed 13 Jun 2023XLO Xilio Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—13,200 at $0.00filing
1 Mar 2023filed 3 Mar 2023Surface Oncologyoption or derivativeSEC FORM 4 Code A—400,000 at $0.00filing
3 Aug 2022filed 5 Aug 2022Surface OncologySEC FORM 4 Sold$18K10,594 at $1.72filing
15 Jun 2022filed 17 Jun 2022XLO Xilio Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—26,400 at $0.00filing
1 Mar 2022filed 3 Mar 2022Surface Oncologyoption or derivativeSEC FORM 4 Code A—359,000 at $0.00filing
1 Mar 2022filed 3 Mar 2022Surface OncologySEC FORM 4 Code A—56,000 at $0.00filing
21 Jul 2021filed 14 Jan 2022Surface OncologySEC FORM 4 Sold$204K33,500 at $6.10filing
16 Feb 2021filed 18 Feb 2021Surface OncologySEC FORM 4 Sold$11K1,000 at $11.35filing
12 Feb 2021filed 11 Mar 2021Surface Oncologyoption or derivativeSEC FORM 4 Code A—484,280 at $0.00filing
12 Feb 2021filed 3 Mar 2021Surface Oncologyoption or derivativeSEC FORM 4 Code A—484,280 at $0.00filing
15 Jan 2021filed 15 Jan 2021Surface OncologySEC FORM 4 Sold$25K2,000 at $12.25filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed10

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.